← Product Code [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX) · K973867 # SCHWARTZ ELECTRO-OPTICS, INC. CRYSTALASE 755 LASER SYSTEM (K973867) _Schwartz Electro-Optics, Inc. · GEX · Feb 10, 1998 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K973867 ## Device Facts - **Applicant:** Schwartz Electro-Optics, Inc. - **Product Code:** [GEX](/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX.md) - **Decision Date:** Feb 10, 1998 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4810 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use The Schwartz Electro-Optics, Inc. CrystaLase 755 is indicated for removal of tattoos of various types and colors and benign epidermal pigmented lesions. ## Device Story CrystaLase 755 is a laser system designed for dermatological procedures. It functions by emitting laser energy to target and remove tattoos of various types/colors and benign epidermal pigmented lesions. Operated by trained clinicians in a clinical setting, the device utilizes laser technology similar to existing predicate laser systems. The clinician directs the laser output at the target tissue to achieve therapeutic removal. The device benefits patients by providing a mechanism for the removal of unwanted tattoos and pigmented lesions. ## Clinical Evidence No clinical data provided; substantial equivalence is based on technological characteristics and similarity to predicate devices. ## Technological Characteristics Laser system; 755 nm wavelength; mechanical and electronic design similar to existing laser systems. Specific materials and standards not disclosed. ## Regulatory Identification (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K973867 ## 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS IX. SCHWARTZ ELECTRO-OPTICS, Inc. CRYSTALASE 755 FEB 1 0 1998 From a technology perspective, theory of operation of all the aforementioned devices are While the laser mediums are identical, all the systems are similar both all the same. mechanically and electronically. Schwartz Electro-Optics, Inc. believes that the technological characteristics of the CrystaLase 755 are similar to the predicate lasers. In regards to safety or effectiveness of the Schwartz Electro-Optics, Inc. CrystaLase 755, Schwartz Electro-Optics, Inc. believes that the slight differences in the performance characteristics of these devices raises no concerns. - Advisory: This information was prepared for the sole purpose of compliance with the Safe Medical Devices Act of 1990. It does not imply that the procedures described herein can be performed with the equipment described without substantial risk of personal injury or death to patients due to operator error or in procedures requiring a high degree of skill. {1}------------------------------------------------ Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with its wings spread, enclosed within a circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged around the upper portion of the circle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Timothy J. Shea Director of the Solid State Laser Division Schwartz Electro-Optics, Incorporated 3404 North Orange Blossom Trail Orlando, Florida 32804 FEB 1 0 1998 Re: K973867 Trade Name: Schwartz Electro-Optics, Inc. CrystaLase 755 Laser System Regulatory Class: II Product Code: GEX Dated: January 6, 1998 Received: January 6, 1998 Dear Mr. Shea: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements , as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for {2}------------------------------------------------ Page 2 - Mr. Shea devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours. Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ 510(k) Number (If known): 510(k) Number (If known): K 973867 Device Name: Schwartz Electro-Optics, Inc. CrystaLase 755 Indications for Use: The Schwartz Electro-Optics, Inc. CrystaLase 755 is indicated for removal of tattoos of various types and colors and benign epidermal pigmented lesions. (Please Do Not Write Below This Line - Continue on Another Page If Needed) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use Or (Division Sign-Off) Division of General Restorative Devices 510k) Number K473867 Over-The-Counter Use (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K973867](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GEX/K973867) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com